US 2025/0051473 A1Published application

Anti-cd38 binding molecules and uses thereof

AssigneeIGM Biosciences, Inc.

InventorsKeyu LI, Paul R. HINTON, Ramesh BALIGA, Bruce Alan KEYT

Life of this patent

Estimating the term…

Abstract

This disclosure provides an antibody or antigen-binding fragment or derivative thereof that specifically binds to CD38. Also provided are polynucleotides encoding the antibody or antigen-binding fragment or derivative thereof and vectors and host cell comprising said poly nucleotides. This disclosure further provides methods for producing and/or using an antibody or antigen-binding fragment or derivative thereof that specifically binds to CD38.

Claims65

Dependent claims

An antibody or antigen-binding fragment or derivative thereof comprising an antigen-binding domain that specifically binds to CD38, wherein the antigen-binding domain comprises a heavy chain variable region (VH) and light chain variable region (VL), wherein the VH and VL comprise six immunoglobulin complementarity determining regions HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3,

wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise, respectively, the amino acid sequences of SEQ ID NO:
65, SEQ ID NO:
66, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
57, SEQ ID NO:
58, SEQ ID NO:
59, SEQ ID NO:
61, SEQ ID NO:
62, and SEQ ID NO:
63;
SEQ ID NO:
73, SEQ ID NO:
74, SEQ ID NO:
75, SEQ ID NO:
77, SEQ ID NO:
78, and SEQ ID NO:
79;
SEQ ID NO:
81, SEQ ID NO:
82, SEQ ID NO:
83, SEQ ID NO:
85, SEQ ID NO:
86, and SEQ ID NO:
87;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
93, SEQ ID NO:
94, and SEQ ID NO:
95;
SEQ ID NO:
97, SEQ ID NO:
98, SEQ ID NO:
99, SEQ ID NO:
101, SEQ ID NO:
102, and SEQ ID NO:
103;
SEQ ID NO:
105, SEQ ID NO:
106, SEQ ID NO:
107, SEQ ID NO:
109, SEQ ID NO:
110, and SEQ ID NO:
111;
SEQ ID NO:
113, SEQ ID NO:
114, SEQ ID NO:
115, SEQ ID NO:
117, SEQ ID NO:
118, and SEQ ID NO:
119;
SEQ ID NO:
121, SEQ ID NO:
122, SEQ ID NO:
123, SEQ ID NO:
125, SEQ ID NO:
126, and SEQ ID NO:
127;
SEQ ID NO:
65, SEQ ID NO:
134, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
65, SEQ ID NO:
182, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
65, SEQ ID NO:
135, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
143, SEQ ID NO:
94, and SEQ ID NO:
95;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
144, SEQ ID NO:
94, and SEQ ID NO:
95;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
145, SEQ ID NO:
94, and SEQ ID NO:
95;
or SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
146, SEQ ID NO:
94, and SEQ ID NO:
95.

109 more elements

An antibody or antigen-binding fragment or derivative thereof comprising an antigen-binding domain that specifically binds to CD38, wherein the antigen-binding domain comprises a heavy chain variable region (VH) and light chain variable region (VL), wherein the VH and VL comprise, respectively, the amino acid sequence of SEQ ID NO:

147 and SEQ ID NO:
150;
SEQ ID NO:
147 and SEQ ID NO:
151;
SEQ ID NO:
147 and SEQ ID NO:
152;
SEQ ID NO:
147 and SEQ ID NO:
153;
SEQ ID NO:
147 and SEQ ID NO:
154;
SEQ ID NO:
147 and SEQ ID NO:
155;
SEQ ID NO:
148 and SEQ ID NO:
150;
SEQ ID NO:
148 and SEQ ID NO:
151;
SEQ ID NO:
148 and SEQ ID NO:
152;
SEQ ID NO:
148 and SEQ ID NO:
153;
SEQ ID NO:
148 and SEQ ID NO:
154;
SEQ ID NO:
148 and SEQ ID NO:
155;
SEQ ID NO:
149 and SEQ ID NO:
150;
SEQ ID NO:
149 and SEQ ID NO:
151;
SEQ ID NO:
149 and SEQ ID NO:
152;
SEQ ID NO:
149 and SEQ ID NO:
153;
SEQ ID NO:
149 and SEQ ID NO:
154;
SEQ ID NO:
149 and SEQ ID NO:
155;
SEQ ID NO:
156 and SEQ ID NO:
159;
SEQ ID NO:
156 and SEQ ID NO:
160;
SEQ ID NO:
156 and SEQ ID NO:
161;
SEQ ID NO:
157 and SEQ ID NO:
159;
SEQ ID NO:
157 and SEQ ID NO:
160;
SEQ ID NO:
157 and SEQ ID NO:
161;
SEQ ID NO:
158 and SEQ ID NO:
159;
SEQ ID NO:
158 and SEQ ID NO:
160;
or SEQ ID NO:
158 and SEQ ID NO:
161.

77 more elements

A multimeric antibody comprising two, four, five, or six bivalent binding units, wherein each binding unit comprises two IgM or IgA heavy chain constant regions or multimerizing fragments or variants thereof, each associated with an antigen-binding domain, wherein at least three, four, five, six, seven, eight, nine, ten, eleven, or twelve of the antigen-binding domains are a CD38 antigen binding domain comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL comprise six immunoglobulin complementarity determining regions HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise, respectively, the amino acid sequences of SEQ ID NO:

65, SEQ ID NO:
66, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
57, SEQ ID NO:
58, SEQ ID NO:
59, SEQ ID NO:
61, SEQ ID NO:
62, and SEQ ID NO:
63;
SEQ ID NO:
73, SEQ ID NO:
74, SEQ ID NO:
75, SEQ ID NO:
77, SEQ ID NO:
78, and SEQ ID NO:
79;
SEQ ID NO:
81, SEQ ID NO:
82, SEQ ID NO:
83, SEQ ID NO:
85, SEQ ID NO:
86, and SEQ ID NO:
87;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
93, SEQ ID NO:
94, and SEQ ID NO:
95;
SEQ ID NO:
97, SEQ ID NO:
98, SEQ ID NO:
99, SEQ ID NO:
101, SEQ ID NO:
102, and SEQ ID NO:
103;
SEQ ID NO:
105, SEQ ID NO:
106, SEQ ID NO:
107, SEQ ID NO:
109, SEQ ID NO:
110, and SEQ ID NO:
111;
SEQ ID NO:
113, SEQ ID NO:
114, SEQ ID NO:
115, SEQ ID NO:
117, SEQ ID NO:
118, and SEQ ID NO:
119;
SEQ ID NO:
121, SEQ ID NO:
122, SEQ ID NO:
123, SEQ ID NO:
125, SEQ ID NO:
126, and SEQ ID NO:
127;
SEQ ID NO:
65, SEQ ID NO:
134, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
65, SEQ ID NO:
182, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
65, SEQ ID NO:
135, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
143, SEQ ID NO:
94, and SEQ ID NO:
95;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
144, SEQ ID NO:
94, and SEQ ID NO:
95;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
145, SEQ ID NO:
94, and SEQ ID NO:
95;
or SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
146, SEQ ID NO:
94, and SEQ ID NO:
95.

108 more elements

A multimeric antibody comprising two, four, five, or six bivalent binding units, wherein each binding unit comprises two IgM or IgA heavy chain constant regions or multimerizing fragments or variants thereof, each associated with an antigen-binding domain, wherein at least three, four, five, six, seven, eight, nine, ten, eleven, or twelve of the antigen-binding domains are a CD38 antigen binding domain comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL comprise, respectively, the amino acid sequence of SEQ ID NO:

147 and SEQ ID NO:
150;
SEQ ID NO:
147 and SEQ ID NO:
151;
SEQ ID NO:
147 and SEQ ID NO:
152;
SEQ ID NO:
147 and SEQ ID NO:
153;
SEQ ID NO:
147 and SEQ ID NO:
154;
SEQ ID NO:
147 and SEQ ID NO:
155;
SEQ ID NO:
148 and SEQ ID NO:
150;
SEQ ID NO:
148 and SEQ ID NO:
151;
SEQ ID NO:
148 and SEQ ID NO:
152;
SEQ ID NO:
148 and SEQ ID NO:
153;
SEQ ID NO:
148 and SEQ ID NO:
154;
SEQ ID NO:
148 and SEQ ID NO:
155;
SEQ ID NO:
149 and SEQ ID NO:
150;
SEQ ID NO:
149 and SEQ ID NO:
151;
SEQ ID NO:
149 and SEQ ID NO:
152;
SEQ ID NO:
149 and SEQ ID NO:
153;
SEQ ID NO:
149 and SEQ ID NO:
154;
SEQ ID NO:
149 and SEQ ID NO:
155;
SEQ ID NO:
156 and SEQ ID NO:
159;
SEQ ID NO:
156 and SEQ ID NO:
160;
SEQ ID NO:
156 and SEQ ID NO:
161;
SEQ ID NO:
157 and SEQ ID NO:
159;
SEQ ID NO:
157 and SEQ ID NO:
160;
SEQ ID NO:
157 and SEQ ID NO:
161;
SEQ ID NO:
158 and SEQ ID NO:
159;
SEQ ID NO:
158 and SEQ ID NO:
160;
or SEQ ID NO:
158 and SEQ ID NO:
161.

77 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/719,191Filed 3 Feb 2023
Priority: 3 Feb 2022
Published: 13 Feb 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification20 codes

C07K 16/2896
Against receptors, cell surface antigens or cell surface determinants: against molecules with a "CD"-designation, not provided for elsewhere
A61P 35/00
Antineoplastic agents
C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies

Family

Application63/306,434Us provisional application · filed 3 Feb 2022
Application63/370,025Us provisional application · filed 1 Aug 2022
Application63/383,736Us provisional application · filed 15 Nov 2022
US 2025/0051473 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise, respectively, the amino acid sequences of SEQ ID NO:
65, SEQ ID NO:
66, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
57, SEQ ID NO:
58, SEQ ID NO:
59, SEQ ID NO:
61, SEQ ID NO:
62, and SEQ ID NO:
63;
SEQ ID NO:
73, SEQ ID NO:
74, SEQ ID NO:
75, SEQ ID NO:
77, SEQ ID NO:
78, and SEQ ID NO:
79;
SEQ ID NO:
81, SEQ ID NO:
82, SEQ ID NO:
83, SEQ ID NO:
85, SEQ ID NO:
86, and SEQ ID NO:
87;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
93, SEQ ID NO:
94, and SEQ ID NO:
95;
SEQ ID NO:
97, SEQ ID NO:
98, SEQ ID NO:
99, SEQ ID NO:
101, SEQ ID NO:
102, and SEQ ID NO:
103;
SEQ ID NO:
105, SEQ ID NO:
106, SEQ ID NO:
107, SEQ ID NO:
109, SEQ ID NO:
110, and SEQ ID NO:
111;
SEQ ID NO:
113, SEQ ID NO:
114, SEQ ID NO:
115, SEQ ID NO:
117, SEQ ID NO:
118, and SEQ ID NO:
119;
SEQ ID NO:
121, SEQ ID NO:
122, SEQ ID NO:
123, SEQ ID NO:
125, SEQ ID NO:
126, and SEQ ID NO:
127;
SEQ ID NO:
65, SEQ ID NO:
134, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
65, SEQ ID NO:
182, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
65, SEQ ID NO:
135, SEQ ID NO:
67, SEQ ID NO:
69, SEQ ID NO:
70, and SEQ ID NO:
71;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
143, SEQ ID NO:
94, and SEQ ID NO:
95;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
144, SEQ ID NO:
94, and SEQ ID NO:
95;
SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
145, SEQ ID NO:
94, and SEQ ID NO:
95;
or SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
146, SEQ ID NO:
94, and SEQ ID NO:
95.

109 more elements

Facts

Application

18/719,191Filed 3 Feb 2023

Priority

3 Feb 2022

Published

13 Feb 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

C07K 16/2896
Against receptors, cell surface antigens or cell surface determinants: against molecules with a "CD"-designation, not provided for elsewhere
A61P 35/00
Antineoplastic agents
C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies